SEC Filing Summary: ADVENTRX Pharmaceuticals, Inc.
Business Context and Reporting Period
This Form 8-K was filed by ADVENTRX Pharmaceuticals, Inc. on October 6, 2010. The report discloses a material event under Item 8.01 (Other Events) regarding intellectual property developments. Note: The request metadata references "Savara Inc," but the filing text explicitly identifies the registrant as ADVENTRX Pharmaceuticals, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 10/889,226. The patent is entitled "Compositions for Delivering Highly Water Soluble Drugs."
Guidance, Outlook, and Risks
The filing does not contain financial guidance, forward-looking outlook statements, or specific risk factors beyond the standard incorporation of the press release. The event signifies a positive milestone in the company's intellectual property portfolio.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for details on the patent's commercial implications.
- Confirm the status of the patent issuance and any associated maintenance fees or timelines.
- Review the company's broader pipeline to understand how this specific patent for water-soluble drug delivery fits into their product strategy.
- Check subsequent filings to ensure the patent was officially granted and issued.